ESMO – European Society for Medical Oncology shared a post on LinkedIn:
“In an Opinion piece in the ESMO Daily Reporter, Elene Mariamidze discusses presentations at ESMO Gynae25 that explore age-related treatment of Gynaecologic Cancer.
A registry analysis in Ovarian Cancer revealed that in patients ≥75 years, 65% received suboptimal surgical treatment and 50% received suboptimal chemotherapy. Four-year overall survival (OS) rates were only 58% for older patients versus 87% for younger patients. When older patients received optimal treatment, a 4-year OS rate of 89% was achieved, highlighting that age itself is not the limiting factor, but access to guideline-concordant care is.
Furthermore, results from the DUO-E trial showed that durvalumab, with or without olaparib, added to carboplatin/paclitaxel was effective irrespective of age in newly diagnosed advanced/recurrent Endometrial Cancer.
Read her full article here.”
More posts featuring ESMO on OncoDaily.